Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Evixapodlin SCHEMBL21274280 | 1.00 | PDCD1 (1.00) | PDCD1CD274 | |
| Evixapodlin SCHEMBL26331593 | 1.00 | PDCD1 (1.00) | PDCD1CD274 | |
| Evixapodlin SCHEMBL29387636 | 1.00 | PDCD1 (1.00) | PDCD1CD274 | |
| Evixapodlin SCHEMBL21290535 | 1.00 | PDCD1 (1.00) | PDCD1CD274 | |
| SCHEMBL26332126 | 0.96 | PDCD1 (1.00) | PDCD1CD274 | |
| SCHEMBL26330471 | 0.96 | PDCD1 (0.93) | PDCD1CD274 | |
| SCHEMBL21291051 | 0.96 | PDCD1 (1.00) | PDCD1CD274 | |
| SCHEMBL26321686 | 0.96 | PDCD1 (0.93) | PDCD1CD274 | |
| SCHEMBL21291064 | 0.96 | PDCD1 (1.00) | PDCD1CD274 | |
| SCHEMBL21289965 | 0.96 | PDCD1 (1.00) | PDCD1CD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4227302-A1 | PD-1/PD-L1 INHIBITORS | Gilead Sciences, Inc. (US) | 2023-08-16 | — | — | EP | disclosed |
| US-20230212155-A1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES, INC. | 2023-07-06 | — | — | US | disclosed |
| US-20210053946-A1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2021-02-25 | — | — | US | disclosed |
| US-10710986-B2 | PD-1/PD-L1 inhibitors | GILEAD SCIENCES, INC. (US) | 2020-07-14 | — | — | US | disclosed |
| US-20190270727-A1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES, INC. | 2019-09-05 | — | — | US | disclosed |
| WO-2019160882-A1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2019-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212155-A1 | PD-1/PD-L1 INHIBITORS | PDCD1, CD274, PDCD1LG2 | PDCD1 1/4885CD274 2/4885 |
| US-20210053946-A1 | PD-1/PD-L1 INHIBITORS | PDCD1, CD274, PDCD1LG2 | PDCD1 1/4885CD274 2/4885 |
| US-10710986-B2 | PD-1/PD-L1 inhibitors | PDCD1, CD274, PDCD1LG2 | PDCD1 1/4885CD274 2/4885 |
| US-20190270727-A1 | PD-1/PD-L1 INHIBITORS | PDCD1, CD274, PDCD1LG2 | PDCD1 1/4885CD274 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.